Physician
Ashland Integrative Medicine LLC
Ashland Integrative Medicine LLC was paid $19.33M by Medicaid between Jan 2018 and Dec 2024, across 54 billing codes. Its largest line is T2023, Targeted case management; per month — 20% of everything it billed.
33Billing provider infoASHLAND INTEGRATIVE MEDICINE LLC
ASHLAND, KY 41102
ASHLAND, KY 41102
33aNPI1982099438assigned 04/01/2015
33bProvider typeObesity Medicine (Family Medicine) Physician
28Total paid$19.33M
24GClaims345,460
24DCodes billed54
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 72,454 | $4.30M | |
| 2019 | 66,982 | $3.83M | |
| 2020 | 53,917 | $3.43M | |
| 2021 | 61,900 | $2.80M | |
| 2022 | 47,257 | $2.20M | |
| 2023 | 24,189 | $1.50M | |
| 2024incomplete | 18,761 | $1.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T2023 | Targeted case management; per month | 20% | 13,435 | 12,062 | $3.92M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 19% | 84,506 | 31,909 | $3.64M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 77,930 | 36,988 | $2.94M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 13% | 18,641 | 7,135 | $2.49M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 7.8% | 12,261 | 9,848 | $1.51M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 6.0% | 34,590 | 18,376 | $1.16M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 6.0% | 14,497 | 9,009 | $1.15M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3.4% | 6,836 | 4,280 | $649K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 2.1% | 29,221 | 14,712 | $400K |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | 1.8% | 5,975 | 2,202 | $344K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.3% | 4,331 | 3,499 | $251K |
| H0038 | Self-help/peer services, per 15 minutes | 1.3% | 16,705 | 8,401 | $250K |
42 more codes
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | 1.1% | 2,743 | $221K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 3,179 | $135K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 791 | $72K |
| H0001 | Alcohol and/or drug assessment | <1% | 523 | $44K |
| 90837 | Psychotherapy session, about an hour | <1% | 464 | $32K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,208 | $29K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 197 | $23K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 318 | $23K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 194 | $10K |
| 80306 | <1% | 896 | $10K | |
| 99385 | <1% | 105 | $3K | |
| 90838 | <1% | 42 | $1K | |
| 99406 | <1% | 132 | $948.24 | |
| 80361 | <1% | 36 | $682.38 | |
| 80363 | <1% | 36 | $682.38 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 60 | $495.88 |
| 90756 | <1% | 29 | $466.97 | |
| 80348 | <1% | 39 | $412.18 | |
| 80344 | <1% | 39 | $412.18 | |
| 80355 | <1% | 39 | $412.18 | |
| 80325 | <1% | 39 | $412.18 | |
| 80354 | <1% | 39 | $412.18 | |
| 80356 | <1% | 39 | $412.18 | |
| 80349 | <1% | 39 | $412.18 | |
| 80365 | <1% | 36 | $378.76 | |
| 80360 | <1% | 36 | $378.76 | |
| 80353 | <1% | 36 | $378.76 | |
| 80368 | <1% | 36 | $378.76 | |
| 80358 | <1% | 36 | $378.76 | |
| H0049 | Alcohol and/or drug screening | <1% | 105 | $378.00 |
| 99386 | <1% | 12 | $350.10 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 24 | $316.52 |
| 80377 | <1% | 29 | $300.78 | |
| 81002 | <1% | 182 | $249.41 | |
| 96103 | <1% | 29 | $206.98 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 58 | $112.10 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 14,423 | $31.24 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 23 | $0.78 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 14 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 136 | $0.00 |
| G8938 | Bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible | 0% | 55 | $0.00 |
| G0436 | Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPARIKH, MANISH (PHYSICIAN)
| Provider | Location | Paid |
|---|---|---|
| Midwest Senior Living LLC | Caledonia, MN | $789K |
| Aim Wellness LLC | Ashland, KY | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.